Tech Company Financing Transactions
Blue Earth Therapeutics Funding Round
Blue Earth Therapeutics, operating out of Oxford, secured $76.5 million from Sands Capital Management, Soleus Capital and Bracco.
Transaction Overview
Company Name
Announced On
10/31/2024
Transaction Type
Venture Equity
Amount
$76,500,000
Round
Series A
Investors
Sands Capital Management (Lead Investor)
Soleus Capital (Lead Investor)
Proceeds Purpose
The new funding enables the company to further advance its clinical stage PSMA-targeted radioligand therapies.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
The Oxford Science Park Magdalen Centre, Robert Robinson Ave
Oxford, OX4 4GA
UK
Oxford, OX4 4GA
UK
Phone
Email Address
Overview
Blue Earth Therapeutics is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat cancer patients. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has a strong pipeline of precision targeted radiopharmaceuticals. Their initial focus is on prostate cancer, with plans to expand to additional disease areas within cancer care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Gauden
VP - General Counsel
Chelsea Roche
Browse more venture capital transactions:
Prev: 10/31/2024: Naptha AI venture capital transaction
Next: 10/31/2024: GlassFlow venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs